ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

31 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  

29 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Arcutis Appoints Interim Chief Financial Officer (CFO)

18 авг 2023 16:30:00 Источник Nasdaq GlobeNewswire

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

10 авг 2023 08:16:31 Источник Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

08 авг 2023 16:02:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 авг 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

17 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 июл 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

06 июн 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 июн 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Leadership Transition

24 май 2023 17:00:03 Источник Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

09 май 2023 16:02:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 май 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

02 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

28 апр 2023 16:01:57 Источник Nasdaq GlobeNewswire

Arcutis to Report First Quarter Financial Results

25 апр 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

18 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

12 апр 2023 16:45:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 апр 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

05 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire